195 related articles for article (PubMed ID: 33291073)
41. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
42. Human splicing factor ASF/SF2 encodes for a repressor domain required for its inhibitory activity on pre-mRNA splicing.
Dauksaite V; Akusjärvi G
J Biol Chem; 2002 Apr; 277(15):12579-86. PubMed ID: 11801589
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
[TBL] [Abstract][Full Text] [Related]
44. Genetic analysis of the SR protein ASF/SF2: interchangeability of RS domains and negative control of splicing.
Wang J; Xiao SH; Manley JL
Genes Dev; 1998 Jul; 12(14):2222-33. PubMed ID: 9679066
[TBL] [Abstract][Full Text] [Related]
45. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.
Araki S; Dairiki R; Nakayama Y; Murai A; Miyashita R; Iwatani M; Nomura T; Nakanishi O
PLoS One; 2015; 10(1):e0116929. PubMed ID: 25581376
[TBL] [Abstract][Full Text] [Related]
46. HIV Rev-dependent binding of SF2/ASF to the Rev response element: possible role in Rev-mediated inhibition of HIV RNA splicing.
Powell DM; Amaral MC; Wu JY; Maniatis T; Greene WC
Proc Natl Acad Sci U S A; 1997 Feb; 94(3):973-8. PubMed ID: 9023367
[TBL] [Abstract][Full Text] [Related]
47. The splicing-factor oncoprotein SF2/ASF activates mTORC1.
Karni R; Hippo Y; Lowe SW; Krainer AR
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15323-7. PubMed ID: 18832178
[TBL] [Abstract][Full Text] [Related]
48. Manipulation of alternative splicing by a newly developed inhibitor of Clks.
Muraki M; Ohkawara B; Hosoya T; Onogi H; Koizumi J; Koizumi T; Sumi K; Yomoda J; Murray MV; Kimura H; Furuichi K; Shibuya H; Krainer AR; Suzuki M; Hagiwara M
J Biol Chem; 2004 Jun; 279(23):24246-54. PubMed ID: 15010457
[TBL] [Abstract][Full Text] [Related]
49. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
[TBL] [Abstract][Full Text] [Related]
50. Targeted disruption of an essential vertebrate gene: ASF/SF2 is required for cell viability.
Wang J; Takagaki Y; Manley JL
Genes Dev; 1996 Oct; 10(20):2588-99. PubMed ID: 8895660
[TBL] [Abstract][Full Text] [Related]
51. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.
Dauksaite V; Akusjärvi G
Biochem J; 2004 Jul; 381(Pt 2):343-50. PubMed ID: 15068396
[TBL] [Abstract][Full Text] [Related]
52. SRPK1/2 and PP1α exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma.
Liu H; Gong Z; Li K; Zhang Q; Xu Z; Xu Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):75. PubMed ID: 33602301
[TBL] [Abstract][Full Text] [Related]
53. PSKH1, a novel splice factor compartment-associated serine kinase.
Brede G; Solheim J; Prydz H
Nucleic Acids Res; 2002 Dec; 30(23):5301-9. PubMed ID: 12466556
[TBL] [Abstract][Full Text] [Related]
54. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
[TBL] [Abstract][Full Text] [Related]
55. Deletion of the N-terminus of SF2/ASF permits RS-domain-independent pre-mRNA splicing.
Shaw SD; Chakrabarti S; Ghosh G; Krainer AR
PLoS One; 2007 Sep; 2(9):e854. PubMed ID: 17786225
[TBL] [Abstract][Full Text] [Related]
56. miR‑30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein.
Huang YQ; Ling XH; Yuan RQ; Chen ZY; Yang SB; Huang HX; Zhong WD; Qiu SP
Mol Med Rep; 2017 Sep; 16(3):2431-2438. PubMed ID: 28677791
[TBL] [Abstract][Full Text] [Related]
57. Novel exploitation of a nuclear function by influenza virus: the cellular SF2/ASF splicing factor controls the amount of the essential viral M2 ion channel protein in infected cells.
Shih SR; Krug RM
EMBO J; 1996 Oct; 15(19):5415-27. PubMed ID: 8895585
[TBL] [Abstract][Full Text] [Related]
58. "Unraveling the tail" of how SRPK1 phosphorylates ASF/SF2.
Mao DY; Ceccarelli DF; Sicheri F
Mol Cell; 2008 Mar; 29(5):535-7. PubMed ID: 18342599
[TBL] [Abstract][Full Text] [Related]
59. A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing.
Tang J; Xie Y; Huang J; Zhang L; Jiang W; Li Z; Bian J
Bioorg Med Chem; 2022 Sep; 70():116921. PubMed ID: 35863237
[TBL] [Abstract][Full Text] [Related]
60. Loss of splicing factor ASF/SF2 induces G2 cell cycle arrest and apoptosis, but inhibits internucleosomal DNA fragmentation.
Li X; Wang J; Manley JL
Genes Dev; 2005 Nov; 19(22):2705-14. PubMed ID: 16260492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
